Home › Company › Publications › Manuscripts

ManuscriptsManuscripts

The following are manuscripts authored or co-authored by C-TASC staff:

Bauserman, Robert

  1. Albertson, AM, Thompson, D, Franko, DL, Holschuh, NM, Bauserman, R, and Barton, BA.  (2009).  Prospective association among cereal intake in childhood and adiposity, lipid levels, and physical activity during late adolescence.  Journal of the American Dietetic Association, 109(10), 1775-80.
  2. Albertson, AM, Affenito, SG, Bauserman, R, Holschuh, NM, Eldridge, AL, and Barton, BA.  (2009).  The relationship of ready-to-eat cereal consumption to nutrient intake, blood lipids, and Body Mass Index of children as they age through adolescence.  Journal of the American Dietetic Association, 109(9), 1557-65.
  3. Franko, DL, Thompson, D, Bauserman, R, Affenito, SG, Striegel-Moore, RH; National Heart, Lung, and Blood Institute Growth and Health Study (NGHS) (2008).  What’s love got to do with it?  Family cohesion and healthy eating behaviors in adolescent girls.  International Journal of Eating Disorders, 41(4), 360-7.
  4. Albertson, AM, Franko, DL, Thompson, D, Eldridge, A, Holschuh, N, Affenito, AG, Bauserman, R, & Striegel-Moore, RH (2007).  Longitudinal patterns of breakfast eating in black and white adolescent girls.  Obesity, 15, 2282-92.
  5. Bauserman, R., & Thompson, D. (2007).  Before and after: Critical event analysis with longitudinal data using SAS.  NESUG 2007, Baltimore, Maryland.
  6. Bauserman, R., Albertson, A., Holschuh, N., & McCarthy, W. (2007a).  Longitudinal cluster analysis with dietary data over time.  SESUG Conference, Hilton Head, South Carolina (Paper DM02).
  7. Bauserman, R., Albertson, A., Holschuh, N., & McCarthy, W. (2007b).  Visual representation of longitudinal change in cluster analysis with SAS.  SESUG Conference, Hilton Head, South Carolina (Paper DP02).
  8. Bauserman, R.L., Richardson, D., Ward, M., Shea, M., Bowlin, C., Tomoyasu, N., & Solomon, S. (2003).  HIV prevention with prison and jail inmates: Maryland’s Prevention Case Management program.  AIDS Education and Prevention, 15, 465-480.
  9. Shifren, K., Furnham, A., & Bauserman, R. (2003).  Emerging adulthood in American and British samples: Individuals’ personality and health risk behaviors.  Journal of Adult Development, 10(2), 75-88.
  10. Bauserman, R. (2002).  Child adjustment in joint-custody versus sole-custody arrangements: A meta-analytic review.  Journal of Family Psychology, 16, 91-102.
  11. Bauserman, R., Ward, M., Eldred, L., & Swetz, A. (2001).  Increasing voluntary HIV testing: Oral and blood testing in incarcerated populations.  American Journal of Public Health, 91, 1226-9.
  12. Kassira, E., Bauserman, R. Tomoyasu, N., Caldeira, E., Swetz, A., & Solomon, L. (2001).  HIV and AIDS surveillance among inmates in Maryland prisons.  Journal of Urban Health, 78, 256-63.
  13. Rind, B., Tromovitch, P., & Bauserman, R. (2001).  The validity and appropriateness of methods, analyses, and conclusions in Rind et al. (1998): A rebuttal of victimological critique from Ondersma et al. (2001) and Dallam et al. (2001).  Psychological Bulletin, 127, 734-58.

 Cheng, Irene

  1. Thorpe LE, Frederick M, Pitt J, Cheng I, Watts H, Buschur S, Green K, Zorrilla C, Landesman S, Hershow R.  Measuring the effects of hard-drug use on CD4 lymphocyte percent, plasma HIV RNA level and progression to AIDS-defining Class C events among HIV-infected women.  JAIDS 2004; 37(3): 1423-30.
  2. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla C, Hammill H, Adeniyi-Jones SK, Thompson B.  The relationship of pregnancy to HIV  disease progression.  Am J Obstetrics and Gynecology  2003; 189:552-9.
  3. Lavigne JE, Shearer WT, Thompson B, Orav EJ, Starc TJ, Colan SD, Pignatelli R, O'Brien SE, Bezold L, LaRusa P, Easley KA, Cheng I, Duffy SA, Lipshultz SE; CHAART Study Group. Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. Cardiovasc Toxicol. 2004;4(2):187-97.
  4. Llorente A, Brouwers P, Thompson B, Cheng I, Macmillan C, Larussa P, Mofenson L, Blasini I, Chase C. Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection. Appl Neuropsychol. 2006;13(3):180
  5. Paredes R, Cheng I, Kuritzkes D, Tuomala R and the Women and Infants Study Group (WITS).  High prevalence of primary lamivudine and nelfinavir resistance in HIV-1 infected pregnant women in the U.S., 1998-2004.  AIDS. 2007 Oct 1;21(15):2103-6.
  6. Shearer WT, Ochs HD, Lee BN, Cohen EN, Reuben JM, Cheng I, Thompson B, Butel JS, Blancher A, Abbal M, Aviles H, Sonnenfeld G. Immune responses in adult female volunteers during the bed-rest model of spaceflight: antibodies and cytokines. J Allergy Clin Immunol. 2009 Apr;123(4):900-5. Epub 2009 Feb

Fish, Billie

  1. Wynn L, Miller S, Faughnan L, Luo Z, Debenham E, Fish B, Hustace T, Kelly T, McDermott M, Marasciulo J, Marshall J, Martin B, McDuffie J, Murphy M, Rackoff B, Reed C, Seaman P, Thomas G, Wang W. Recruitment of infants with sickle cell anemia to a Phase III Trial: data from the BABY HUG study. Contemp Clin Trials  2010; 31:558-563.

Forman, Sandra

  1. The Coronary Drug Project Research Group:  Clofibrate and Niacin in coronary heart disease.  JAMA 1975; 231:360‑81.
  2. The Coronary Drug Project Research Group:  Aspirin in coronary heart disease.  J Chron Dis 1976; 29:625‑42.
  3. Gordon RS, Kahn HA, Forman S:  Altitude and cerebrovascular death rates show apparent relationship.  Stroke 1977; 8:274.
  4. Gordon RS, Forman S, Canner PL, Berge K, Miller D:  Gall­bladder disease as a side effect of drugs influencing lipid metabolism experience in the Coronary Drug Project.  New Engl J Med 1977; 296:1185‑90. 
  5. Gordon RS, Danner RN, Forman S:  Letter to editor.  New Engl J Med 1977; 297:61.
  6. The Coronary Drug Project Research Group:  Clofibrate and gall­bladder disease (letter to the editor).  New Engl J Med 1978; 298:461.
  7. The Coronary Drug Project Research Group:  Estrogens and cancer (letter to the editor).  JAMA 1978; 239:2758‑59. 
  8. Stamler J, Forman S, Krol WF:  The natural history of myocardial infarction in the Coronary Drug Project:  Long‑term prognostic importance of serum lipid levels.  Am J Cardiol 1978; 42:489‑98.
  9. Meinert CL, Forman S, Jacobs DR, Stamler J. for the Coronary Drug Project Research Group:  Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J Chron Dis 1979; 32:415‑25.
  10. Canner PL, Forman SA, Prud'homme GJ, Berge KG, Stamler J: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project.  New Engl J Med 1980; 303:1038‑41.
  11. Schlant RC, Forman S, Stamler J, Canner PL:  The natural history of coronary heart disease:  Prognostic factors after recovery from myocardial infarction in 2789 men ‑ The Five Year Findings of the Coronary Drug Project.  Circulation 1982; 66:401‑1­4.
  12. Klimt CR, Forman S:  Secondary prevention of myocardial infarc­tion with drugs.  Israel Journal of Medical Sciences 1983; 19:460‑70.
  13. Meinert CL, Heinz EC, Forman SA:  Coronary Drug Project:  Methods and Lessons of a Multicenter Clinical Trial.  Chapter 6 "Role and methods of the Coordinat­ing Center."  Controlled Clinical Trials 1983; 4:355‑75.
  14. Knatterud, GL, Forman, SA, Canner, PL:  Coronary Drug Project: Methods and lessons of a multicenter clinical trial.  Chapter 11 "Design of data forms."  Controlled Clinical Trials 1983; 4:429‑40.
  15. Canner PL, Krol WF, Forman SA:  Coronary Drug Project:  Methods and lessons of a multicenter clinical trial.  Chapter 12 "External quality control programs."  Controlled Clinical Trials 1983; 4:441‑6­6.
  16. Forman S, Furberg C, Wenger NK, Stamler J. for the Coronary Drug Project Research Group:  Blood pressure in survivors of myocardial infarction.  J Am Coll Cardiol 1984; 4:1135‑47.
  17. TIMI Study Group.  Thrombolysis in Myocardial Infarction (TIMI) Trials:  Phase I findings.  New Engl J Med 1985; 312:932‑36.
  18. Hillis LD, and TIMI Principal Investigators:  High‑dose intra­venous streptokinase for acute myocardial infarction:  Preliminary results of a multicenter trial.  J Am Coll Cardiol 1985; 6:957‑62.
  19. Williams DO, and TIMI Principal Inves­tigators:  Intravenous recom­binant tissue type plasminogen activator in acute myocardial infarction:  A report from the NHLBI Thrombolysis in Myocardial Infarction (TIMI) Trial.  Circulation 1986; 73:338‑46.
  20. Chesebro JH, and TIMI Principal Investigators:  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I:  A comparison between intravenous tissue plasminogen activator and in­travenous streptokinase.  Clinical findings through hospital discharge.  Circula­tion 1987; 76:1:142‑54. 
  21. Mueller HS, Rao AK, Forman S:  Thrombolysis in Myocardial Infarc­tion (TIMI):  Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue type plasminogen activator.  J Am Coll Cardiol 1987; 10:479‑90.
  22. Passamani E, and TIMI Investigators:  The (TIMI) Thrombolysis in Myocardial Infarction Phase II Pilot:  Tissue plasminogen activator (rt‑PA) followed by percutaneous transluminal coronary angioplasty (PTCA).  J Am Coll Cardiol 1987; 10:5:­51B-64B.
  23. Williams DO, Ruocco NA, Forman S:  Coronary angioplasty following tissue‑type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction Trial.  J Am Coll Cardiol 1987; 10:5:45B-50B.
  24. Knatterud GL, Forman, SA:  Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial.  NHLBI Recruit­ment Workshop, April 1986.  Controlled Clinical Trials 1987; 8:86S-93S.
  25. Dalen DE, Gore JM, Braunwald E, et al:  Six- and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial.  Am J Cardiol 1988; 62:4:179-85.
  26. Rogers WJ, Bourge RC, Papapietro SE, Wackers FHT, Zaret BL, Forman S, Dodge HT, Robertson TL, Passamani ER, Braunwald E, and TIMI Investigators:  Variables predictive of good functional outcome following thrombolytic therapy in the Throm­bolysis in Myocardial Infarction Phase II (TIMI II) Pilot Study.  Am J Cardiol 1989; 63:503-12.
  27. Wackers JTH, Terrin ML, Kayden DS, Knatterud, GL, Forman S, Braunwald E, Zaret BL, and TIMI Investigators:  Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction:  Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial.  J Am Coll Cardiol 1989; 13:998-1005. 
  28. TIMI Study Group: Comparison of invasive and conservative stra­tegies following intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.  New Engl J Med 1989; 320:618-27.
  29. Hillis LD, Forman S, Braunwald E, and the TIMI Investigators:  Risk stratification in patients with acute myocardial infarction receiving thrombolytic therapy.  J Am Coll Cardiol 1990; 16:313-5.
  30. Roberts R, Rogers W, Mueller HS, Lambrew CT, Diver DJ, Smith HC, Willerson JT, Knatterud GL, Forman S, Passamani E, Zaret BL, Wackers FJT, Braunwald E.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.  Circulation 1991; 83:422-37.
  31. Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, Forman S, Knatterud G, Sopko G, Terrin ML.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma following acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study (TIMI II Pilot and Clinical Trial).  Circulation 1991; 83:448-59.
  32. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R, and the TIMI Investigators.  Influence of coronary collateral vessels on myocardial infarct size in man: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial.  Circulation 1991; 83:739-46.
  33. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI Investigators.  Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II:  Predictors of Early Morbidity and Mortality.  Circulation 1992; 85:1254-64.
  34. Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, Braunwald E. and the TIMI Research Group.  Modifiers of Timing and Possible Triggers of Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI) Study Group.  J Am Coll Cardiol 1992; 20:1049-55.
  35. Terrin M, Williams DO, Kleiman NS, Willerson J, Mueller HS, Desvigne-Nickens P, Forman SA, Knatterud GL, Braunwald E, for the TIMI II Investigators.  Two- and Three-Year Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial.  J Am Coll Cardiol 1993; 22:1763-72. 
  36. Cox DA, Rogers WJ, Aguirre FV, Forman S, Solomon R and the TIMI Investigators.  Presence or Absence of Chest Pain at Initiation of Lytic Therapy:  Effect on Outcome in Acute MI.  Am J Cardiol 1994; 73:729-736. 
  37. Pepine CJ, Geller NL, Knatterud GL, Bourassa MG, Chaitman BR, Davies RF, Day P, Deanfield JE, Goldberg AD, McMahon RP, Mueller H, Ouyang P,  Pratt C, Proschan M, Rogers WJ, Selwyn AP, Sharaf B, Sopko G, Stone PH, Conti CR for the ACIP Investigators.  The Asymptomatic Cardiac Ischemia Pilot (ACIP) study:  Design of a randomized clinical trial, baseline data and implications for a long-term outcome trial.  J Amer Coll Cardiol 1994; 24:1-10. 
  38. Knatterud GL, Bourassa MG, Pepine CJ, Geller NL, Sopko G, Chaitman BR, Pratt C, Stone PH, Davies RF, Rogers WJ, Deanfield JE, Goldberg AD, Ouyang P, Mueller H, Sharaf B, Day P, Selwyn AP, Conti CR for the ACIP Investigators.  Effects of treatment strategies to suppress ischemia in patients with coronary artery disease:  12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.  J Amer Coll Cardiol 1994: 11-20.
  39. Sloan MA, Price TR, Petito C., Randall AMY, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, Babb J, Herman M, Roberts WC, Sopko G, Bovill E, Forman S, Knatterud GL for the TIMI Investigators.  Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The TIMI II pilot and randomized trial combined experience.  Neurology 1995; 45:649-658.
  40. Zaret BL, Wackers FJ, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E.  Value of radionuclide rest and exercise left ventricular ejection fraction to assess survival of patients following thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II Study.  J Am Coll Cardiol 1995; 26:73-9. 
  41. Chaitman BR, Stone PH, Knatterud GL, Forman SA, Sopko G, Bourassa MG, Pratt C, Rogers WJ, Pepine CJ, Conti CR for the ACIP Investigators.  Asymptomatic Cardiac Ischemia Pilot (ACIP) Study:  Impact of anti-ischemia therapy on 12-week rest ECG and exercise test outcomes.  J Am Coll Cardiol 1995; 26:585-93.
  42. Rogers WJ, Bourassa MG, Andrews TC, Bertolet BD, Blumenthal RS, Chaitman B, Forman S, Geller NL, Goldberg AD, Habib GB, Masters RG, Moisa RB, Mueller H, Pearce DJ, Pepine C, Sopko G, Steingart RM, Stone PH, Knatterud GL, Conti CR for the ACIP Investigators.  The Asymptomatic Cardiac Ischemia Pilot (ACIP) Study:  Outcome at one year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization.  J Am Coll Cardiol 1995; 26:594-605
  43. Bourassa MG, Pepine CJ, Forman SA, Rogers WJ, Dyrda I, Stone PH, Chaitman BR, Sharaf B, Mahmarian J, Davies RF, Knatterud GL, Terrin M, Sopko G, Conti CR for the ACIP Investigators.  Asymptomatic Cardiac Ischemia Pilot (ACIP) Study:  Effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia.  J Am Coll Cardiol 1995; 26:606-14.
  44. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E for the TIMI Investigators.  Prognostic significance of nonfatal reinfarction during 3-year follow-up:  Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial.  J Am Coll Cardiol 1995; 26:900-7. 
  45. Bourassa MG, Knatterud GL, Pepine CJ, Sopko G, Rogers WJ, Geller NL, Dyrda I, Forman SA, Chaitman BR, Sharaf B, Davies RF, Conti CR for the ACIP Investigators.  Asymptomatic Cardiac Ischemia Pilot (ACIP):  Improvement of cardiac ischemia at 1 year following PTCA and CABG.  Circulation 1995; 92(suppl II):II-1-II-7.
  46. Hall C, Cannon C, Forman S, Braunwald E for the TIMI II Investigators.  Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured with the first 12 hours after myocardial infarction.  J Amer Coll Cardiol 1995; 26:1452-6.
  47. McKendall GO, Forman S, Sopko G, Braunwald E, Williams DO and the Thrombolysis in Myocardial Infarction Investigators.  Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction.   Am J Cardiol 1995; 76:1108-11.
  48. Caracciolo EA, Chaitman BR, Forman SA, Stone PH, Bourassa MG, Sopko G, Geller NL, Conti CR for the ACIP Investigators:  Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring compared to that of nondiabetic patients:  An ACIP Database Study.  Circulation 1996; 93:2097-2105.
  49. Pepine CJ, Andrews T, Deanfield JE, Forman S, Geller N, Hill JA, Pratt C, Rogers WJ, Sopko G, Steingart R, Stone PH, Conti CR for the ACIP Investigators.  Relationship of patient characteristics to cardiac ischemia during daily life activity:  An ACIP Data Bank Study.  Am J Cardiol 1996; 77:1267-72. 
  50. Steingart RM, Forman S, Coglianese ME, Bittner V, Mueller H, Frishman W, Handberg E, Gambino A, Knatterud G, Conti CR.  Factors limiting the enrollment of women in a randomized coronary artery disease trial.  Clinical Cardiology 1996; 19:614-18.
  51. Becker LC, Pepine CJ, Bonsall R, Cohen JD, Goldberg AD, Coghlan C, Stone PH, Forman S, Knatterud G, Sheps DS, Kaufmann P.G. for the PIMI Investigators.  Left ventricular, peripheral vascular, and neurohumoral responses to mental stress in normal middle-aged men and women: Reference group for the Psychophysiologic Investigations of Myocardial Ischemia (PIMI) Study.  Circulation 1996; 94:2768-77.
  52. Conti CJ, Geller N, Knatterud G, Forman S, Pratt C, Pepine C, Sopko G for the ACIP Investigators. Definitions of status and prediction of one year outcomes in patients with coronary artery disease enrolled in the Asymptomatic Cardiac Ischemia Pilot (ACIP). Am J Cardiol 1997; 79:889-92.
  53. Mahmarian JJ, Steingart RM, Forman S, Sharaf BL, Coglianese ME, Miller DD, Pepine CJ, Goldberg AD, Bloom MF, Byers S, Dvorak L, Pratt CM for the ACIP Investigators.  Relationship between ambulatory electrocardiographic monitoring and myocardial perfusion imaging to detect coronary artery disease and myocardial ischemia: An ACIP Ancillary Study. J Am Coll Cardiol 1997; 29:764-9. 
  54. Davies R, Goldberg D. Forman S, Pepine C, Knatterud G, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study two Year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95:2037-43.   
  55. Conti CJ, Geller N, Knatterud G, Forman S, Pratt C, Pepine C, Sopko G for the ACIP Investigators.  Anginal Status and Prediction of Cardiac Events in Patients Enrolled in the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.  Am J Cardiol 1997;79:889-892.
  56. Pepine CJ, Sharaf B, Andrews TC, Forman S, Geller N, Knatterud G, Mahmarian J, Ouyang P, Rogers WJ, Sopko G, Steingart R, Stone PH, Conti CR for the ACIP Study Group.  Relation Between Clinical, Angiographic and Ischemia Findings at Baseline and Ischemia-Related Adverse Outcomes at 1 Year In the Asymptomatic Cardiac Ischemia Pilot Study.  J Am Coll Cardiol1997;29:1483-9.
  57. Stone PH, Chaitman BR, Forman S, Andrews TC, Bittner V, Bourassa MG, Davies RF, Deanfield JE, Frishman W, Goldberg AD, MacCallum G, Ouyang P, Pepine CJ, Pratt CM, Sharaf B, Steingart R, Knatterud GL, Sopko G, Conti CR for the ACIP Investigators.  Prognostic Significance of Myocardial Ischemia Detected by Ambulatory Electrocardiography, Exercise Treadmill Testing, and Electrocardiogram at Rest to Predict Cardiac Events by One Year (The Asymptomatic Cardiac Ischemia Pilot [ACIP] Study.  Am J Cardiol 1997;80:1395-1401.
  58. Davies RF for the ACIP Investigators.  The Need for a Prognosis Trial of Revascularization and Aggressive Medical Therapy in Patients with Asymptomatic Cardiac Ischemia.  Clin Cardiol 1998;21:154-156.
  59. Handberg-Thurmond E, Baker A, Coglianese ME, Forman S, Pepine CJ, Geller N, Chaitman B for the ACIP Group.  Identifying High Yield Sources of Coronary Artery Disease for Clinical Trials: Lessons from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Experience.  Clin Cardiol 1998;21:177-182.
  60. Frishman WH, Gomberg-Maitland M, Hirsch H, Catanese J, Furia-Palazzo S, Mueller H, Steingart R, Forman S for the Asymptomatic Cardiac Ischemia Pilot (ACIP) Investigators.  Differences Between Male and Female Patients with Regard to Baseline Demographics and Clinical Outcomes in the Asymptomatic Cardiac Ischemia Pilot (ACIP) Trial.  Clin Cardiol 1998;21:184-190.
  61. Gobel FL, Stewart WJ, Campeau L, Hickey A, Herd JA, Forman S, White CW, Rosenberg Y for the Post CABG Clinical Trial Investigators.  Safety of coronary arteriography in clinically stable patients following coronary bypass surgery.  Catheterization and Cardiovascular Diagnosis 1998;45:376-381.
  62. Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ, Rosenberg Y for the Post CABG Trial Investigators.  Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, in the Elderly, and Patients with Associated Risk Factors: NHLBI Post Coronary Artery Bypass Graft Clinical Trial. Circulation 1999;99:3241-3247.
  63. Alaupovic P, Fesmire JD, Hunninghake D, Domanski M, Forman S, Knatterud GL, Forrester J, Gobel F, Herd AJ, Hoogwerf B, Campeau L.  The Effect of Aggressive and Moderate Lowering of LDL-Cholesterol and Low Dose Anticoagulation on Plasma Lipids, Apolipoproteins and Lipoprotein Families in Post Coronary Artery Bypass Graft Trial.  Atherosclerosis 1999;146:369-379.
  64. Pepine CJ, Mark DB, Bourassa MG, Chaitman BR, Davies RF, Knatterud GL, Forman S, Pratt CM, Sopko G and Conti CR for the ACIP Study Group.  Cost Estimates for Treatment of Cardiac Ischemia:  An Ancillary Study from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study.  Am J Cardiol 1999;84:1311-1316. 
  65. Pepine CJ, Bourassa MG, Chaitman BR, Davies RF, Kerensky RA, Sharaf B, Knatterud GL, Forman SA, Pratt CM, Staples ED, Sopko G, and Conti CR for the ACIP Study Group.  Factors Influencing Clinical Outcomes after Revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP).  J Card Surg 1999;14:1-8.
  66. Ketterer MW, Freedland KE, Krantz DS, Kaufmann P, Forman SA, Greene A, Raczynski J, Knatterud G, Light K, Carney RM, Stone P, Becker L, Sheps D for the PIMI Investigators.  Psychological correlates of mental stress-induced ischemia in the laboratory: The Psychophysiological Investigation of Myocardial Ischemia (PIMI) Study.  Journal of Health Psychology 2000;5(1):75-85.
  67. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C and Post CABG Investigators.  The Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial.  Circulation 2000;102:157-165.
  68. Walenga JM, Hoppensteadt D, Pifarre R, Fox NL, Forman S, Hunninghake DB, Campeau L, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML.  The hemostatic effects of warfarin titration in Post CABG patients in comparison to placebo treatment.  Journal of Thrombosis and Thrombolysis 2001;11:143-149.
  69. White C, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML and the Post CABG Investigators.  Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the Post Coronary Artery Bypass Graft Trial.  Circulation 2001;104:2660-2665.
  70. Schulman SP, Thiemann DR, Ouyang P, Chandra NC, Schulman DS, Reis SE, Terrin M, Forman S, de Albuquerque CP, Bahr RD, Townsend SN, Cosgriff R, Gerstenblith G.  Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina.  J Am Coll Cardiol 2002;39:231-7. 
  71. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, Forman SA for the Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT).  Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery.  A randomized controlled trial.  JAMA 2002;287:1943-1951.
  72. Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y and the Post CABG Investigators.  Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.  Am Heart J 2003;145:262-9.
  73. Davis AR, Robilotto CM, Westhoff CL, Forman S, Zhang for the NICHD Management of Early Pregnancy Failure Trial Group.  Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure.  Human Reproduction 2004;19:1655-58.
  74. The Occluded Artery Trial (OAT) Research Group.  Design and methodology of the Occluded Artery Trial (OAT).  Am Heart J 2005; 150:627-42.
  75. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith G.  L-Arginine therapy in acute myocardial infarction.  The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial.  JAMA 2006; 295:1:58-64.
  76. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL for the Occluded Artery Trial Investigators.  Coronary intervention for persistent occlusion after myocardial infarction.  N Engl J Med 2006;355(23):2395-407.
  77. Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GB J, Cantor WJ, Carere RJ, Ross JR, Atchison D, Forman S, Thomas B, Buszman P, Vozzi C, Glanz A, Cohen EA, Meciar P, Devlin G, Mascette A, Sopko G, Knatterud GL, Hochman JS, for the TOSCA-2 Investigators.  Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function.  The Total Occlusion Study of Canada (TOSCA)-2 Trial.  Circulation 2006;114(23):2449-57.
  78. Mariusz Kruk, Jacek Kadziela, Harmony R. Reynolds, Sandra A. Forman, Zygmunt Sadowski, Bruce A. Barton, Daniel B. Mark, Aldo P. Maggioni, Jonathan Leor, John G. Webb, Michael Kapeliovich, Jose A. Marin-Neto, Harvey D. White, Gervasio A. Lamas, Judith S. Hochman. Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction. Results From the Occluded Artery Trial (OAT). J Am Col Cardiol. Intv. 2008 1: 511-520. PubMed Central ID#: PMC2635493; PubMed ID#: 19194534; NIH Manuscript Submission ID#: NIHMS82380.
  79. Venu Menon, Camille A. Pearte, Christopher E. Buller, Ph. Gabriel Steg, Sandra A. Forman, Harvey D. White, Paolo N. Marino, Demosthenes G. Katritsis, Paulo Caramori, Ricardo Lasevitch, Krystyna Loboz-Grudzien, Aleksander Zurakowski, Gervasio A. Lamas, Judith S. Hochman. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. Jan 2009; 30:183-191. PubMed Central ID#: PMC2639108; PubMed ID#: 19028780.
  80. Warren J. Cantor, Sergio B. Baptista, Vankeepuram S. Srinivas, Camille A. Pearte, Venu Menon, Zygmunt Sadowski, John R. Ross, Peter Meciar, Eugenia Nikolsky, Sandra A. Forman, Gervasio A. Lamas, Judith S. Hochman. Impact of Stress Testing Prior to PCI or Medical Management on Outcomes of Patients With Persistent Total Occlusion After Myocardial Infarction: Analysis From the Occluded Artery Trial. Am Heart J 2009;157:666-72. PubMed ID#: 19332193.
  81. Eric J. Rashba, Gervasio A. Lamas, Jean-Philippe Couderc, Sharri M. Hollist, Vladimír Džavík, Witold Ruzyllo, Viliam Fridrich, Christopher E. Buller, Sandra A. Forman, Joseph A. Kufera, Antonio C. Carvalho, Judith S. Hochman. Electrophysiological Effects of Late Percutaneous Coronary Intervention for Infarct-Related Coronary Artery Occlusion.  The Occluded Artery Trial – Electrophysiological Mechanisms (OAT-EP). Circulation 2009;119:779-787. PubMed ID#: 19188505.
  82. LA Malek, HR Reynolds, SA Forman, C Vozzi, GB John Mancini, JK French, M Dziarmaga, JP Renkin, J Kochman, GA Lamas, JS Hochman. Late coronary intervention for totally occluded LADs in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). American Heart Journal 2009;157:724-32. PubMed ID#: 19332202.
  83. Džavik V, Buller CE, Devlin G, Carere RG, Mancini GB, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS. Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv. May 1 2009;73(6):771-779. PubMed ID#: 19309733.
  84. Christopher E. Buller, Jamie M. Rankin, Ronald G. Carere, Pawel E. Buszman, Matthias E. Pfisterer, Vladimir Dzavik, Boban Thomas, Sandra Forman, Witold Ruzyllo, G.B. John Mancini, Lampros K. Michalis, Pedro F. Abreu, Gervasio A. Lamas, Judith S. Hochman. Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years. Am Heart J. 2009 Sep;158(3):408-15. PubMed ID#: 19699864
  85. Irene M. Lang, Sandra A. Forman, Aldo P. Maggioni, Witold Ruzyllo, Carlos Vozzi, Jean  Renkin, P. Gabriel Steg, Jose‐Maria Hernandez-Garcia, Krzysztof Zmudka, Manuel Jimenez-Navarro, George Sopko, Gervasio A. Lamas, Judith S. Hochman. Causes of Death in Early MI Survivors With Persistent Infarct Artery Occlusion: Results from the Occluded Artery Trial (OAT).  EuroIntervention.  2009 Nov;5(5): 610-8.  PubMed ID#: 20142183.
  86. Mariusz Kruk, Christopher E. Buller, James E. Tcheng, Vladimir Dzavik, Venu Menon, G.B. John Mancini, Sandra A. Forman, Peter Kurray, Benita Busz-Papiez, Gervasio A. Lamas, Judith S. Hochman. Impact of Left Ventricular Ejection Fraction on Clinical Outcomes Over Five Years Following Infarct Related Coronary Artery Recanalization (from the Occluded Artery Trial [OAT]). Am J Cardiol. 2010 Jan 1; 105 (1):10-6.

Frederick, Margaret

  1. Bryant M: Interval estimation of an effective dose (Ph.D. dissertation), 1986.
  2. Arling G, Capitman JA, Coleman D. Bryant M. Roszell K, Pedrick D, and McTaggart M.  Study of the public and private cost of institutional and community-based long-term care.  Prepared for the Virginia Long-Term Care Council and the Virginia Assembly by the Virginia Center on Aging.
  3. Rogers WJ, Babb JD, Baim DS, Chesebro JH, Gore JM, Roberts R, Williams DO, Frederick M, Passamani ER, Braunwald E for the TIMI Investigators.  Selective versus routine pre-discharge coronary arteriography following therapy with rt-PA, heparin and aspirin for acute myocardial infarction.  J Am Coll Cardiol; 1991; 17(5):1007-16
  4. Bovill E, Terrin ML, Stump DC, Berke A, Frederick M, Collen D. Feit F, Gore J, Hillis LD, Lambrew C, Leiboff R, Mann KG, Markis JE, Pratt C, Sharkey S, Sopko G, Tracy R and Chesebro J for the TIMI Investigators.  Hemorrhagic events during treatment with intravenous recombinant tissue-type plasminogen activator, heparin and aspirin in acute myocardial infarction.  Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.  Annals of Internal Medicine 1991; 4:256-65.
  5. Baim DS, Diver DJ, Feit F, Greenberg MA, Holmes DR, Weiner BH, Williams DO, Schweiger MS, Brown BG, Frederick MM, Knatterud GL and Braunwald E for the TIMI II Investigators.  Coronary angioplasty performed within the Thrombolysis in Myocardial Infarction (TIMI II) Study.  Circulation 1992; Vol 85, No 1.
  6. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP and the TIMI Investigators.  Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II.  J Am Coll Cardiol 1992;20:533-40.
  7. Chaitman BR, McMahon RP, Terrin M, Younis LT, Shaw LJ, Weiner DA, Frederick MM, Knatterud GL, Sopko G, Braunwald E for the TIMI Investigators.  Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial.  American Journal of Cardiology 1993; Vol 71, pp 131-138.
  8. Berger PB, Ruocco NA, Ryan TJ, Jacobs AK, Zaret BL, Wackers FJ, Frederick MM, Faxon DP and the TIMI Research Group.  Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction (TIMI) II Trial.  American Journal of Cardiology 1993; Vol 71.
  9. Van Horn LV, Stumbo P, Moag-Stahlberg A, Obarzanek E, Hartmuller G, Ferris R, Kimm SYS, Frederick M, Snetselaar L, Liu K.  The Dietary Intervention Study in Children (DISC):  Dietary assessment methods for 8-10 year olds.  JADA 1993; Vol 93, No 12. 
  10. Simon JA, Schreiber GB, Crawford PB, Frederick M, Sabry ZI.  Dietary vitamin C and serum lipids in black and white girls.  Epidemiology 1993; Vol 4, No 6.
  11. Simon JA, Schreiber GB, Crawford PB, Frederick MM, Sabry ZI.  Income and racial patterns of dietary vitamin C intake among black and white girls.  Public Health Reports 1993; Vol 108, No 6.
  12. Obarzanek E, Schreiber GB, Crawford PB, Goldman SR, Barrier PM, Frederick MM, Lakatos E.  Energy intake and physical activity in relation to indexes of body fat: the National Heart, Lung, and Blood Institute Growth and Health Study.  American Journal of Clinical Nutrition 1994; Vol 60.
  13. Simon JA, Obarzanek E, Daniels S, Frederick MM.  Dietary cation intake and blood pressure in black girls and white girls.  American Journal of Epidemiology 1994; Vol 139, No 2.
  14. Crawford PB, Obarzanek E, Schreiber GB, Barrier P, Goldman S, Frederick MM, Sabry ZI.  The effects of race, household income, and parental education on nutrient intakes of 9 and 10 year old girls.  AEP 1995; Vol 5, No 5.
  15. Thompson B, Geller NL, Hunsberger S, Frederick M, Hull R, Jacob RG, Smith EA, Kaufmann P, Freedman RR, Wigley FM, Billory L.  Behavioral and pharmacologic interventions: The Raynauds Treatment Study.  Controlled Clinical Trials.  1999; 20:52-63. 
  16. Maricq HR, Jennings JR, Thompson B, Frederick MM, Hill R.  Evaluation of treatment efficacy of Raynaud’s Phenomenon by digital blood pressure response to cooling.  Vascular Medicine 2000; 5: 135-40.
  17. Rybicki B, Iannuzzi M, Frederick M, Thompson B et al. for the ACCESS Research Investigators. Familial aggregation of sarcoidosis: A Case Control Etiologic Study of Sarcoidosis (ACCESS). American Journal of Respiratory and Critical Care Medicine. 2001; 164(11):2085-91. 
  18. Pandey, JP, Frederick MM, and the ACCESS Research Group.  TNF-, IL1-, and Immunoglobulin (GM and KM) Gene Polymorphisms in Sarcoidosis. Human Immunology 2002; 63:485-91.
  19.     Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, Monos D and the ACCESS Group.  HLA-DRB1*1101: A significant risk factor for sarcoidosis in blacks and whites.  Am J Genet 2003; 73:720-35.
  20.     Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla CD, Hammill H, Adeniyi-Jones SK, Thompson B.  The relationship of pregnancy to human immunodeficiency virus disease progression.  Am J Obstet Gynecol 2003; 189 (1):552-9.
  21.     LaMonte AC, Paul ME, Read JS, Frederick MM, Erdman DD, Han LL, Anderson LJ for the Women and Infants Transmission Study.  Persistent parvovirus B19 infection without the development of chronic anemia in HIV-infected and -uninfected children: The Women and Infants Transmission Study.  JID 2004;189: 847.
  22.     Gilles JM, Creinin MD, Barnhart K, Westhoff C, Frederick MM, Zhang J.  A randomized trial of saline solution - moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure.  Am J Obstetrics and Gynecology 2004; 190:389-94.
  23.     Barhart KT, Bader T, Huang C, Frederick MM, Timbers KA, Zhang JJ.  Hormone pattern after misoprostol administration for a nonviable first-trimester gestation.  Fertility and Sterility.  April 2004; 81:1099-1105.
  24.     Crenin MD, Harwood B, Guido RS, Fox MC, Zhang J.  Endometrial thickness after misoprotstol use for early pregnancy failure.  Intern’l J of Gynecology and Obstretrics.  2004; 86:22-6.
  25.     Thorpe LE, Frederick MM, Pitt J, Chang I, Watts DH, Buschur S, Green K, Zorilla C, Landesman SH, Hershow RC.  Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining Class C events among HIV-infected women.  J Acquir Immune Defic Syndr 2004; 37:1423-30.
  26.     Nansel TR, Doyle F, Frederick MM, Zhang J.  Quality of life in women undergoing medical treatment for early pregnancy failure.  J Obstret, Gynecologic and Neo Natal Nursing 2005; 34(4):473-81
  27.     Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM, et al.  A comparison of medical management with misoprostol and surgical management for early pregnancy failure.  N Engl J Med 2005; 353(8):761-769. 
  28.     Pacheco Se, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, Frederick MM, Handelsman E, Hayani K, Shearer WT for the Womens and Infants Transmission Study.  Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the Womens and Infants Transmission Study.  JID 2006; 194:1089.
  29.     Chantry CJ, Frederick MM, Meyer WA, Handelsman E, Rich K, Paul ME, Diaz C, Cooper E, Foca M, Adeniyi-Jones SK, Moye J. Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children.  Pediatr Infect Dis J 2007; 26:53-60.
  30.     Davis AR, Hendlish SK, Westhoff C, Frederick MM, Zhang J. Bleeding patterns following misoprostol vs. surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynocol 2007;196: 31.e1-31.e7.
  31.     Han MK, Bartholmai B, Flaherty KR, Limper A, Schwarz MI, Thannickal VJ, Frederick M, Thompson B, Li D, Toews GB, Martinez FJ.  Gender differences in emotional function in patients with IPF: A Lung Tissue Research Consortium Study. AJRCCM, 2007; 177:A886.
  32.     Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA.  The Bone Mineral Density in Childhood Study (BMDCS): Bone mineral content and density according to age, sex, and race.  J Clin Endocrin Metab. 2007; 92(6):2087-99.
  33.     Rossman MD, Thompson B, Frederick M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Rose C, Magira E, Monos D and the ACCESS Group.  HLA and environmental interactions in Sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:125-132.
  34.     Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, Kazerooni EA, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Freeman C, Landreneau RJ, Wise R, Martinez FJ.  Clinical significance of radiologic characterizations in COPD.  COPD:  Journal of Chronic Obstructive Pulmonary Disease 2009; 6:459-467.

Huang, Xuan

  1. Moonie SA, Huang X, Sterling DA:  Qualify of life estimation with structural equation modeling in school aged children with asthma.  Global Health Governance Journal, 2009, Vol. 3 (1).
  2. Richmond CM, Sterling D, Huang X, Wilston K, Pike E:  Asthma 411 – addition of a consulting physician to enhance school health.  Journal of School Health, 2006, Vol. 76 (6).

Li, Daner

  1. Ruiz B, Garay J, Johnson W, Li D, Rugge M, Dixon MF, Fiocca R, Genta RM, Hattori T, Lechago J, Price AB, Sipponen P, Solcia E, Watanabe H, Correa P.. Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology 2001; 39(3):235-42.
  2. Correa P, Fontham E, Bravo J, Bravo L, Ruiz B, Zarama G, Realpe J, Malcom G, Li D, Johnson W, Mera R.. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. Journal of the National Cancer Institute 2000; 92:1881-88.
  3. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B; Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):449-73
  4. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2007 Mar 1; 44(3):299-305.
  5. Grace M. Aldrovandi, Clara Chu, William T. Shearer, Daner Li, Jan Walter, Bruce Thompson, Kenneth McIntosh, Marc Foca, William A. Meyer, III, Belinda F. Ha, Kenneth C. Rich and Jack Moye, Jr. Antiretroviral Exposure and Lymphocyte mtDNA Content Among Uninfected Infants of HIV-1-Infected Women. Pediatrics 2009;124;e1189-e1197.
  6. Han MK, Swigris J, Liu L, Bartholmai B, Murray S, Giardino N, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Flaherty K, Martinez FJ. Gender influences health-related Quality of Life in IPF. Respir Med. 2009 Dec 23.
  7. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, Kazerooni EA, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Freeman C, Landreneau RJ, Wise R, Martinez FJ. Clinical significance of radiologic characterizations in COPD. COPD. 2009 Dec; 6(6):459-67.
  8. Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, Hughes MD, Tuomala R. Risk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2010 Jan 8.
  9. Scott T. Miller, MD, Winfred C. Wang, MD, Rathi Iyer, MD, Sohail Rana, MD, Peter Lane, MD, Russell E. Ware, MD, PhD, Daner Li, MS, Renée C. Rees, PhD, for the BABY-HUG Investigators. Urine concentrating ability in infants with sickle cell disease: Baseline data from the phase III trial of hydroxyurea (BABY HUG). Pediatr Blood Cancer 2010 Feb; 54(2):265-8.

Liu, Li

  1. Liu L, Forman S, Barton B. Fitting Cox Model Using PROC PHREG and Beyond in SAS.  SAS Global Forum Proceedings, 2009 May; 236-2009.
  2. Overgaard CB, Buller CE, Maggioni AP, Leor J, Ruzyllo W, Burton JR, Reis G, Liu L, Devlin, G Banasiak W, Lamas GA, Hochman, JS and Vladimír Džavík. Late Clinical Outcomes of Diabetic Patients Randomized in the Occluded Artery Trial (OAT). Circulation, Oct 2008; 118: S_661.
  3. Goodman ZD, Makhlouf HR, Liu L, etc.. Pathology of Chronic Hepatitis C in Children: Liver Biopsy Findings in the Peds-C Trial.  Hepatology. 2008 Mar. 47(3): 836-843.
  4. Liu L, Guo N, McCarthy WF.  Gaining Power from GTL and ODS Style to Control Graphical Output.  SAS Global Forum Proceedings, 2007 Apr; 092-2007.
  5. Stothers L, Gourlay WA, Liu L.  Attitudes and Predictive Factors for Live Kidney Donation: a Comparison of Live Kidney Donors versus Non-Donors.  Kidney Int. 2005 Mar; 67(3): 1105-11.
  6. Gourlay WA, Stothers L, Liu L.  Attitudes and Predictive Factors for Live Kidney Donation in British Columbia.  A Comparison of Recipients and Wait-List Patients.  Can J Urol.  2005 Feb; 12(1): 2511-20.
  7. Bassett KL, Noertjojo K, Liu L, Dunzhu S, Wang FS, Tenzing C, Wilkie, A, Santangelo, M, Courtright P.  Cataract surgical coverage and outcome in the Tibet Autonomous Region of China. Br J Ophthalmol. 2005; 89:5-9.
  8. Steven G. Deeks, Christina M. R. Kitchen, Liu L, Hua Guo, Ron Gascon, Amy B. Narváez, Peter Hunt, Jeffrey N. Martin, James O. Kahn, Jay Levy, Michael S. McGrath, Frederick M. Hecht. Immune Activation Set-point During Early HIV Infection Predicts Subsequent CD4+ T Cell Changes Independent of Viral Load.  Blood. 2004 Aug; 104(4):942-7.
  9. Dunzhu S, Wang FS, Courtright P, Liu L, Tenzing C, Noertjojo K, Wilkie A, Santangelo M, Bassett KL. Blindness and eye diseases in Tibet: findings from a randomized, population based survey. Br J Ophthalmol. 2003 Dec; 87(12): 1443-8.
  10. Jacobson MA, Liu L, Khayam-Bashi H, Deeks SG, Hecht FM, Kahn J.  Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy.  AIDS. 2003;17:917-919
  11. Grant RM, Hecht FM, Warmerdam M,  Liu L, Lieglr T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO.  Time Trend in Primary HIV-1 Drug Resistance Among Recently Infected Persons.  JAMA. 2002; 288: 181-188.
  12. J Baverstock RJ, Manson AD, Liu L, Gourlay WA.  A prospective comparison of simultaneous and sequential live-donor renal transplantation.  Transplantation 2002;74:1194-7.
  13. Dam OM, Sibley LM, Law FL, Liu L, Le G, Courtright P.  Reliability and Reproducibility of a Chinese-Language Visual Function Assessment.  Ophthalmic Epidemiol.  2001; 8: 327-337.
  14. Liu L, Liu YL.  Handling Collinearity in Fitting Multiple Linear Regression Models. Chinese Journal of Health Statistics, Vol.11 (1) 5-7, 1994.
  15. Guo J, Liu L, Wei QZ.  A Review of Frequently Used Statistical Methodology in Medical Research during 1989-1993.  Chinese Journal of Health Statistics, Vol.11 (5) 27-29, 1994.
  16. Sun G. Liu L.  Control Confoundings: Using Logistic Regression Model.  Journal of China Medical University,  Vol.23 (2) 184-186, 1994.
  17. Wang ZH, Liu L, Liu YL.  Risk Factors of Colon Cancer in Chinese Population: A Factor Analysis. Chinese Journal of Health Statistics, Vol.10 (6) 5-9, 1993.
  18. Liu L, Liu YL..  Control Confounding: Using Multivariate Confounding Score. Chinese Journal of Health Statistics, Vol.8 (1) 9-11, 1991.
  19. Liu L, Feng YH..  Optimized non-linear transformation in fitting of linear models.  Chinese Journal of Health Statistics, Vol.7 (3) 5-8, 1990.
  20. Liu L, Lin YP etc.  Canonical Correlation Analysis of Factors Influencing Serum thyroid Hormones in Newborns.  Journal of China Medical University, vol.18 (6) 443-445, 1989.

Lu, Ming

  1. Foster SB, Lu M, Thompson B, Rich K, et al.  Association between HLA inheritance and asthma medication use in HIV+ children.  Accepted by AIDS. 
  2. Ouyang D, Brogly S, Lu M, Shapiro D, et al. Lack of increased hepatotoxicity in HIV-infected pregnantwomen receiving nevirapine compared with other antiretrovirals. AIDS. Jan 2010, Vol. 24, No. 1: 109-114.
  3. Ouyang D, Shapiro D, Lu M, Brogly S, et al. Increased risk of hepatotoxicity in HIV-infected pregnantwomen receiving antiretroviral therapy independent of nevirapine exposure. AIDS. Nov 2009, Vol. 23, No. 18:2425-2430.
  4. Watts H, Lu M, Thompson B, Tuomala R, et al. Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infectious diseases in obstetrics and gynecology. Jan 2009, Vol. 2009: 1-9.
  5. Foster SB, McIntosh K, Thompson BW, Lu M, et al. Increased Incidence of Asthma in HIV-Infected Children Treated with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study. J Allergy Clin Immunol. 2008 Jul;122(1):159-65.
  6. Dowd KA, Hershow RC, Yzwetz S., LaRussa P., Diaz C, Landersman SH, Paul ME, Read JS, Lu M, Thomas DL, Ray, SC. Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis. 2008 Dec 1;198(11):1651-1655.
  7. Pacheco SE, McIntosh K, Lu M, et al. Effect of Perinatal Antiretroviral Drug Exposure on Hematologic Values in HIV-Uninfected Children: An Analysis of the Women and Infants Transmission Study. The Journal of Infectious Diseases 2006;194:1089-1097
  8. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005 Jun 10;19(9):953-960.
  9. Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M,  et al. Morbidity and Mortality Among Uninfected Children Born to Human Immunodeficiency Virus Type 1- Infected Women: The Women and Infants Transmission Study. Pediatr Infect Dis J. 2005 Jan;24(1):46-56.
  10. Hershow RC, O'Driscoll PT, Handelsman E, Pitt J, Hillyer G, Serchuck L, Lu M, et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis. 2005 Mar 15;40(6):859-67.
  11. Philpott S., Tarwater PM, Lu M, et al. CCR2 Genotype and Disease Progression in a Treated Population of HIV Type 1 Infected Woman. Clinical Infectious Diseases, volume 39 (2004), pages 861–865.
  12. Lu M., Li R., Li H, et al. Immunologic memory against hepatitis B surface antigen among population of infancy HBV vaccination. Chinese Public Health, Vol.16, No.10, Oct. 2000, p942-945.
  13. Li M, Lu M, Li H, et al. The relationship between nonresponse to hepatitis B vaccine and HLA genotype/haplotype. J. Chinese Preventive Medicine. 2002 May;36(3):180-3.

Quinn, Xiaofei

  1. Weinman EJ, Biswas RS, Peng G, Shen L, Turner CL, E Xiaofei, Steplock D, Shenolikar S and Cunningham R. (2007) “Parathyroid hormone Inhibits renal phosphate transport by phosphorylation of serine 77 of sodium-hydrogen exchanger regulatory factor-1”,The Journal of Clinical Investigation,2007 Nov ; 117(11) : 3412-20.
  2. Cunningham R, Brazie M, Kanumuru S, E Xiaofei, Biswas R,  Wang F, Steplock D,Wade JB, Anzai N, Endou H, Shenolikar S, and Weinman EJ.  (2007)  “Sodium-Hydrogen Exchanger Regulatory Factor-1 Interacts with Mouse Urate Transporter 1 to Regulate Renal Proximal Tubule Uric Acid Transport”, Journal of the American Society of Nephrology, 2007 May;18(5):1419-25. Epub 2007 Apr 4.
  3. Cunningham R, Steplock D, E Xiaofei, Biswas RS, Wang F, Shenolikar S, and Weinman EJ. (2006) “Adenoviral expression of NHERF-1 in NHERF-1 null Mouse renal proximal tubule cells restores Npt2a regulation by low Phosphate media and parathyroid hormone”, American Journal of Physiology. Renal Physiology, 2006 Oct;291(4):F896-901. Epub 2006 May 16.
  4. Cunningham R, E Xiaofei, Steplock D, Shenolikar S, and Weinman EJ. (2005) “Defective PTH regulation of Sodium-dependent phosphate transport in NHERF-1-/-renal Proximal tubule cells and wild-type cells adapted to low-phosphate Media”, American Journal of Physiology. Renal Physiology,2005 Oct;289(4):F933-8. Epub 2005 Jun 7.
  5. Cunningham R, Steplock D, Wang F, Huang H, E Xiaofei, Shenolikar S, and Weinman EJ. (2004) “Defective Parathyroid Hormone Regulation of NHE3 Activity and Phosphate Adaptation in Cultured NHERF-1-/-Renal Proximal Tubule Cells”, The Journal of Biological Chemistry, 2004 Sep 3;279(36):37815-21. Epub 2004 Jun 24.

Thompson, Bruce

  1. Gordis L, Szklo M, Thompson B, Kaplan E, Tonascia J.  An apparent increase in the incidence of acute non-lymphocytic leukemia in black children.  Cancer, 1981; 47(11):2763-68.
  2. Nirankri V, Karesh J, Thompson B:  Reply to letter to the editor regarding "A prospective clinical study of radial keratotomy. Ophthal­mology, 1982; 89(11):1292-93.
  3. Egorin M, Van Echo DA, Olman E, Whitacre M, Tipping S, Thompson B, and Aisner J.  Pharmakokinetics and dosage reduction of carboplatin in patients with impaired renal function.  Cancer Research, 1984; 44:5432-38.
  4. Hankins JR, Mayer RF, Satterfield JR, Turney SZ, Attar S, Sequeira AJ, Thompson BW, and McLaughlin JS.  Thymectomy for myasthenia gravis:  Fourteen-Year experience.  Annals of Surgery, 1985; 201(5):61­8-24.
  5. Johnson DE, Thompson B, Calia FM.  Comparative activities of piperacil­lin, ceftazidime and amikacin alone and in all possible combinations, against experimental pseudomonas aeruginosa infec­tions in neutropenic rats.  Antimicrobial Agents and Chemotherap­y, 1985; 27:735-39.
  6. Hogge DE, Thompson B, Schiffer CA.  Platelet storage for seven days in second generation blood bags.  Transfusion, 1986; 26:131-35.
  7. Levine MS, Fox NL, Thompson B, Taylor W, Darlington AC, Van der Hoeden J, Emmett EA, Rutten W.  Inhibition of esterase activity and an under-counting of circulating monocytes in a population of production workers.  Journal of Occupational Medicine, 1986; 28(3):20­7-11.
  8. Johnson DE and Thompson BW.  Efficacy of single agent therapy with azlocillin, ticarcillin and amikacin and beta-lactam/amikacin combina­tions for treatment of pseudomonas aeruginosa bacteremia in granulocyto­penic rats.  American Journal of Medicine, 1986; 80:53-58.
  9. de Jongh CA, Joshi JH, Thompson BW, Newman KA, Finley RS, Moody MR, Salvatore PC, Tenney JH, Drusano GL and Schimpff SC.  A double beta-lac­tam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.  American Journal of Medicine, 1986; 80:101-11.
  10. Ross DD, Thompson BW, Joneckis CC, Akman SA and Shiffer CA.  Metabolism of ara-C by blast cells from patients with ANLL.  Blood, 1986; 68:76.
  11. Attar S, Miller JE, Hankins J, Thompson BW, Suter CM, Kragel PJ, McLaughlin JS.  Bronchial astenoma:  A review of 51 cases.  Annals of Thoracic Surgery, 1986; 40(2):126-32.
  12. Balcer-Kubiczek EK, Harrison GH and Thompson BW.  Repair time for oncogenic transformation in C3H/Lo TL/2 cells subject to protracted x-irradiation.  International Journal of Radiation Biology, 1987; 51(2):219-26.
  13. Poplin E, Thompson BW, Whitacre M, Aisner J.  Small cell carcinoma of the lung (SCCL):  Influence of age on treatment outcome.  Cancer Treatment Reports, 1987; 71:291-96. 
  14. Thompson B, Rohde C.  Probability of response models and DNA repair:  A statistical-biological approach.  Mathematical Bio­sciences, 1987; 84(2):139-54.
  15. Fox NL, Sexton MS, Hebel R and Thompson BW.  The reliability of self-reports of smoking and alcohol consumption by pregnant women.  Addictive Behaviors 1989; 14:187-95.
  16. Ross DD, Thompson BW, Joneckis CC, Akman SA, Schiffer CA.  Studies of ara-C metabolism in acute leukemia.  Seminars in Oncology, 1987; 14:182-91.
  17. Ross DD, Ordonez JV, Joneckis CC, Testa JR, Thompson BW.  Isolation of highly multidrug-resistant P388 cells from drug-sensitive P388/S cells by flow cytometric cell sorting.  Cytometry 1988; 9:359-67.
  18. Ross DD, Thompson BW, Ordonez JV and Joneckis CC.  Improvement of flow cytometric detection of multi-drug resistant cells by cell volume normalization of intracellular daunorubicin content.  Cytometry, 1989; 10:185-91.
  19. Terrin M, Goldhaber SZ, Thompson BW.  Selection of patients with acute pulmonary embolism for thrombolytic therapy.  Chest May, 1989; (supplement) 95: 279s-281s. 
  20. Orr S, James SA, Burns BJ, Thompson BW.  Chronic stressors in maternal depression:  Implications for prevention.  American Journal of Public Health 1989; 79(9):1295-96.
  21. Chaitman BR, Thompson B, Wittry MD, Stump D, Hamilton WP, Hillis LD, Dwyer JG, Solomon RE, Knatterud GL, and TIMI Inves­tigators.  The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: Results from Thrombolysis in Myocardial Infarction Phase I, Open Label Studies and the Thrombolysis in Myocardial Infarction Phase II Pilot Study.  J Am Coll Cardiol 1989; 14:1159-65.
  22. Chaitman BR, Thompson BW, Kern MJ, Vandormael MG, Cohen MB, Ruocco NA, Solomon RE, Braunwald EB for the TIMI Investigators: Tissue plasminogen activator followed by percutaneous transluminal coronary an­gioplasty: One-year TIMI Phase II pilot results.  Am Heart J February 1990; 119(2):213-23.
  23. The PIOPED Investigators.  Value of the ventilation/perfusion scan in acute pulmonary embolism.  J Am Med Assoc May, 1990; 263(20):2753-59.
  24. The PIOPED Investigators.  Tissue plasminogen activator for the treatment of acute pulmonary embolism.  Chest 1990; 97:528-33.
  25. The T3A Investigators.  Early Effects of Tissue Plasminogen Activator Added to Conventional Therapy, on the Culprit Artery Lesion in Patients Presenting with Ischemic Cardiac Pain at Rest.  Circulation January, 1993: 87(1):38-52.
  26. Fisher CJ, Dhainaut JFA, Opal SM, et al.  Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome.  Results from a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol 1994; 27, 1836-43. 
  27. The TIMI IIIB Investigators.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction.  Circulation 1994; 89; 1545-56. 
  28. Diver DJ, Bier JD, Ferreria PE, et al.  Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).  Am J Cardiol 1994; 74:531-7. 
  29. Cannon CP, Thompson B, McCabe CH, Mueller HS, Kirshenbaum JM, Herson S, Nasmith JB, Chaitman BR, Braunwald E for the TIMI III Investigators.  Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes:  An analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials.  Am J Cardiol 1995;75:977-981.
  30. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe C, Knatterud GL, Thompson B, Willerson JT, Braunwald E for the TIMI-IIIB Investigators.  One-Year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB Clinical Trial:  A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction.  J Am Coll Cardiol 1995;26:1643-50. 
  31. Kleiman NS, Anderson HV, Rogers WJ, Theroux P, Thompson B, Stone PH.   Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting.  Am J Cardiol 1996;77:227-231.
  32. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald E for the TIMI III Investigators.  Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial).  Am J Cardiol 1996;78:142-147. 
  33. Becker RC, Cannon CP, Tracy RP, Thompson BW, Bovill EG, Desvigne-Nickens P, Randall AMY, Knatterud GL, Braunwald E for the Thrombolysis In Myocardial Ischemia IIIB Investigators.  Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction.  American Heart Journal 1996;131:421-33.
  34. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Rogers WJ, Diver DJ, Theroux P, Warnica JW, Nasmith JB, Kells C, Kleiman N, McCabe CH, Schactman M, Knatterud GL, Braunwald E for the TIMI III Registry Investigators.  Influence of Race, Sex, and Age on Management of Unstable Angina and Non-Q-Wave Myocardial Infarction.  The TIMI III Registry.  JAMA 1996;275:1104-1112.
  35. Williams DO, Braunwald E, Thompson B, Sharaf BL, Buller CE, Knatterud GL for the TIMI IIIB Investigators.  Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction:  Observations from the TIMI IIIB Trial.  Circulation 1996;94:2749-2755.
  36. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.  New England Journal of Medicine 1996;335:1342-9.
  37. Cannon CP, McCabe CH, Stone PH, Schactman M, Thompson B, Theroux P, Gibson RS, Feldman T, Kleiman NS, Tofler GH, Muller JE, Chaitman BR, Braunwald E for the TIMI IIIB Investigators.  Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (The TIMI IIIB Registry and TIMI IIIB).  American Journal of Cardiology 1997;79:253-8.
  38. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald E.  Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, Phase IIIB Trial).  Am J Cardiol 1997;79:391-396.
  39. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D.  An application of the Zucker-Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) Clinical Trial.  Controlled Clin Trials 1997;18:318-327.
  40. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, Pearce DJ, Diver DJ, Kells C, Feldman T, Williams M, Gibson RS, Kronenberg MW, Ganz LI, Anderson HV, Braunwald E for the TIMI III Registry ECG Ancillary Study Investigators. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q-wave myocardial infarction: Results of the TIMI III Registry Ancillary Study.  Journal of the American College of Cardiology 1997;30:133-40.
  41. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E for the TIMI Investigators.  Outcome and profile of women and men presenting with acute coronary syndromes: A report from TIMI IIIB.  J Am Coll Cardiol 1997;30:141-8.
  42. Jain D, Thompson B, Wackers FJ, Zaret BL for the TIMI-IIIB Study Investigators.  Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study.  Journal of the American College of Cardiology 1997;30(2):421-9.
  43. Callas PW, Tracy RP, Bovill EG, Cannon C, Thompson B, Mann KG.  The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial.  J Thromb Thrombolysis 1998; 5(1): 53-60. 
  44. Thompson B, Geller NL, Hunsberger S, Frederick M, Hill R, Jacob RG, Smith EA, Kaufmann P, Freedman RR, Wigley FM and Bielory L.  Behavioral and Pharmacologic Interventions:  The Raynaud’s Treatment Study.  Controlled Clin Trials 1999;20:52-63.
  45. Kostrikis LG, Neumann AU, Thompson B et al.  A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants.  Journal of Virology 1999; 73: 10264-10271. 
  46. Maricq HR, Jennings JR, Valter I, Frederick M, Thompson B, Smith EA, Hill R.  Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling.  Raynaud’s Treatment Study investigators.  Vasc Med 2000; 5(3):135-40.
  47. Raynaud’s Treatment Study investigators.  Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary raynaud phenomenon.  Arch Intern Med 2000; 160:1101-08.
  48. Read JS, Tuomala R, Kpamegan E, Zorrilla C, Landesman S, Brown G. Vajaranant M, Hammill H, Thompson B.  Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study.  J Acquir Immune Defic Syndr 2001; 26:236-45.
  49. Sadanandan S, Buller C, Menon V, Dzavik V, Terrin M, Thompson B, Lamas G, Hochman, J.  The late open artery hypothesis–a decade later.  Am Heart J 2001;142:411-21.
  50. Thompson BW, Knatterud GL.  Interim Monitoring Plans to Simultaneously Evaluate a Composite End Point and a Severe Adverse Event that is Part of the Composite End Point.  Controlled Clin Trials 2001; 22:32S. 
  51. Middaugh SJ, Haythornthwaite JA, Thompson B, Hill R, Brown KM, Freedman RR, Attanasio V, Jacob RG, Scheier M, Smith EA.  The Raynaud’s Treatment Study: Biofeedback protocols and acquisition of temperature biofeedback skills.  Applied Psychophysiology and Biofeedback, December 2001;26.
  52. Thompson BW, Jacob RG, Frederick M. Geller NV, Hunsberger S.  Innovative designs in behavioural trials.  Statist Med 2002; 21:2981-9. 
  53. Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, Monos D and the ACCESS Group.  HLA-DRB1*1101: A significant risk factor for sarcoidosis in blacks and whites.  Am J Genet 2003; 73:720-35.
  54. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, Pitt J, Zorrilla CD, Hammill H, Adeniyi-Jones SK, Thompson B.  The relationship of pregnancy to human immunodeficiency virus disease progression.  Am J Obstet Gynecol 2003; 189(1): 552-9. 
  55. Sexton MJ, Fischkoff SA, Hobbins TE, Mabuchi K and Thompson BW.  A randomized clinical trial of 30 mg. beta-carotene in male smokers.  Association of Community Cancer Centers, Washington, D.C., March, 1985.
  56. Sigman LM, Eqorin MJ, Cohen BE and Thompson BW.  In-vivo evaluation of adriamycin (adr) and continuous verapamil (V) infusion against murine P388 leukemia.  American Association of Cancer Research, 1986.
  57. Drusano GL, Thompson B, Tatem B, Standiford HC.  A novel method of examining synergy testing of antimicrobials.  Clinical Research 1986; 34(2).
  58. Mackenzie CF, Watson R, Pyne A, Baekhyo S, Moorman R and Thompson BW.  Are cardiac oscillations a mechanism of gas-exchange with en­dobronchial insufflation?
  59. Critical Care Medicine 1986; 14:14:384.
  60. Thompson B, Handy C and Terrin M.  Imputing missing values under order restrictions.  Controlled Clinical Trials September 1988; 9(3):262.
  61. Thompson B, Knatterud GL.  The use of factorial designs when the outcome variable is binary:  What happens when low level interactions are present.  Controlled Clinical Trials September, 1989; 10(3):323.
  62. Thompson B, Barton F.  Visualizing the effect of time-dependent covariates using the Cox Model:  A simple method and application.  Controlled Clinical Trials October, 1991; 12(5):618. 
  63. Thompson B, Ross R.  Getting more power from pair-wise comparisons in a three group design while protecting the experiment-wise error rate.  Controlled Clinical Trials October, 1991; 12(5):685.
  64. Thompson B.  The influence of missing data in the analysis of composite end points.  Controlled Clinical Trials October, 1991; 12(5):685.
  65. Terrin M, Frederick M, Thompson BW, Knatterud GL, and the TIMI Investigators.  Observational analyses with time dependency and missing values in the Thrombolysis in Myocardial Infarction (TIMI) II clinical trial.  Cont Clin Trials 1992; 13:383.
  66. Williams DO, Sharaf BL, Braunwald E, Thompson B, Knatterud GL, Buller CE, and the TIMI-III Investigators.  Percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction: The TIMI-III Experience.  Supplement to Circulation 1994;90:I-433.
  67. Sharaf BL, Rivera W, Miele NJ, Thompson B, McKendall GR, Riley RS, Drew TM, Thomas ES, Williams DO for the TIMI 3 Investigators.  Coronary anatomy in patients who present with non-Q-wave myocardial infarction differs from unstable angina pectoris: A report from TIMI-IIIB.  Supplement to Circulation 1994;90:I-664.
  68. Buller CE, Fung AY, Thompson BW, Ricci DR, Thompson B, Schactman M, Williams DO.  Does pre-treatment with TPA improve safety of coronary angioplasty in acute coronary syndrome?  Results of TIMI IIIB.  Supplement to Circulation 1994;90:I-22.
  69. Williams DO, Thompson B, Braunwald E, Knatterud GL, Sharaf BL, Stone PH.  Contemporary PTCA for acute coronary ischemia:  Results in women match those of men.  Supplement to Journal of the American College of Cardiology 1995; 25(Suppl A):138A. 
  70. Williams DO, Thompson B, Braunwald E, Knatterud GL, Sharaf BL, Stone PH.  Advanced age does not diminish the results of PTCA for acute ischemic syndromes.  Supplement to Journal of the American College of Cardiology 1995; 25(Suppl A):346A. 
  71. Canner J, Thompson B, LoPresti F, Knatterud GL, Campeau L, Domanski M, Forrester J, Gobel F, Herd A, Hoogwerf B, Hunninghake D, Walenga J and the POST CABG Investigators.  Analysis of the titration procedure for warfarin in the Post Coronary Bypass Graft (POST CABG) Clinical Trial.  Controlled Clinical Trials 1997;18:3S:175S.
  72. Thompson B, Forman S, Terrin M.  The analysis of transformed count data in clinical trials.  Controlled Clinical Trials 1997;18:3S:131S.
  73. Thompson BW, Knatterud GL.  Interim Monitoring Plans to Simultaneously Evaluate a Composite End Point and a Severe Adverse Event that is Part of the Composite End Point.  Controlled Clin Trials 2001; 22:32S.
  74. Middaugh SJ, Haythornthwaite JA, Thompson B, Hill R, Brown KM, Freedman RR, Attansio V, Jacob RG, Scheier M, Smith EA.  The Raynaud’s Treatment Study: biofeedback protocols and acquisition of temperatture biofeedback skills.  Appl Psychophysiol Biofeedback 2001; 26(4): 251-78.
  75. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, DePalo L, Hunninghake G, Johns C, Judson MA, Knatterud GL, McLennan G, Newman LS, Rabin DL, Rose C. Teirstein AS, Weinberger SE, Yeager H, Cherniack R: ACCESS Research Group.  Familial aggregation of sarcoidosis: A case-control etiologic study of sarcoidosis (ACCESS).  Am J Respir Crit Care Med 2001; 164(11): 2085-91.
  76. Read JS, Tuomala R, Kpamegan E, Zorrilla C, Landesman S, Brown G, Vajaranant M, Hammill H, Thompson B.  Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study.  JAIDS.  2001; 26:236-45. 
  77. Rossman M, Thompson B, Frederick M, Cizman B, Magira E, Monos D.  Sarcoidosis: association with human leukocyte antigen class II amino acid epitopes and interaction with environmental exposures.  Chest 2002; 121(3): 14S.
  78. Judson MA, Baughman RP, Thompson BW, Teirstein AS, Terrin ML, Rossman MD, Yeager H Jr., McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR. Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Chernaick R.  ACCESS Research Group.  Two year prognosis of sarcoidosis: the ACCESS experience.  Sarcoidosis Vasc Diffuse Lung Dis 2003; 20(3): 204-11.
  79. Judson MA, Thompson BW, Rabin DL, Steimel J, Knatterud GL, Lackland DT, Rose C, Rand CS, Baughman RP, Teirstein AS, ACCESS Research Group.  The diagnostic pathway to sarcoidosis.  Chest 2003; 123(2): 406-12.
  80. Minkoff H, Hershow R, Watts DH, Frederick M. Cheng I, Tuomala R, Pitt J, Zorrilla C, Hammill H, Adeniyi-Jones SK, Thompson B.  The relationship of pregnancy to HIV disease progression.  American Journal of Obstretics and Gynecology  2003; 189:552-59.
  81. Rabin DL, Thompson B, Brown KM, Judson MA, Huang X, Lackland DT, Kantterud GL, Yeager H Jr., Rose C, Steimel J.  Sarcoidosis: social predictors of severity at presentation.  Eur Respir J 2004; 24(4), 601-8.
  82. Lavigne JE, Shearer WT, Thompson B, Orav EJ, Starc TJ, Colan SD, Pignatelli R, O’Brien SE, Bezold L, LaRussa P, Easley KA, Cheng I, Duffy SA, Lipsultz SE, CHAART Study group.  Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. Cardiovasc Toxicol 2004; 4(2): 187-97.
  83. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager Jr. H, Johns CJ.  A Case Control Etiologic Study of Sarcoidosis: Environmental and Occupational Risk Factors.  Am J Respir Crit Care Med 2004; Sept. 3.
  84. Ioannidis JP, Tatsioni A, Abrams EJ, Bultreys M, Coombs RW, Goedert JJ, Korber BT, Mayaux MJ, Mofenson LM, Moye J Jr., Newell ML, Shapiro DE, Teglas JP, Thompson B, Wiener J.  Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis.  AIDS 2004; 18(1):99-108.
  85. Tuomala R, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, Landesman S, Zorrilla C, Thompson B for the Women and Infant Transmission Study (WITS).  Antiretroviral therapy including HAART during pregnancy associated with few maternal and obstetrical adverse outcomes. J Acquir Immune Defic Syndr.  2005; 38(4): 449-73.
  86. Barnard J, Rose C, Newman L, Canner M, Martyny J, McCammon C, Bresnitz E, Rossman M, Thompson B, Rybicki B, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Teirstein AS, Yeager H, Johns CJ, Rabin DL, Cherniack R and the ACCESS Research Group.  Job and industry classifications associated with sarcoidosis in a Case-Control Etiologic Study of Sarcoidosis (ACCESS).  J Occup Environ Med 2005; 47:226-34.
  87. Kreider ME, Christie JD, Thompson B, Newman L, Rose C, Barnard J, Bresnitz E, Judson MA, Lackland DT, Rossman MD for the ACCESS Research Group.  Chest 2005; 128:207-15. 
  88. The Occluded Artery Trial (OAT) Research Group.  Design and methodology of the Occluded Artery Trial (OAT).  Am Heart J.  2005; 150:627-42.
  89. Lipshultz SE, Shearer, WT, Rich K, Thompson B, Cheng I, Harmon T, Orav EJ, Pignatelli RH, Bezold LI, La Russa P, Starc TJ, Glickstein J, O’Brien S, McIntosh K, Cooper ER, Colan SD. Antiretroviral therapy (ART)-associated cardiotoxicity in uninfected but ART-exposed infants born to HIV-infected women: The prospective NHLBI CHAART-1 Study.  Circulation 112 (17): II-421 (#2004) (2005).
  90. Watts H, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B.  Assessment of birth defects according to maternal therapy among infants in the women and infants transmission study. JAIDS 2006.
  91. Mellins CA, Chu C, Malee K, et al.  Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women.  AIDS Care.  In Press. 
  92. Shearer W, Pahwa S, Read J, Chen J, Wijayawardana SR, Palumbo P, Abrams EJ, Nesheim SR, Yin W, Thompson B, Easley KA.  CD4/CD8 T-cell ratio predicts HIV infection in infants: The NHLBI P2C2 HIV Study.  J Allergy Clin Immunol 2007; 120:1449-56. 
  93. Thompson BW, Chu C, Richards T.  (2007), Sample size estimation for factorial designs in miroarray studies. 2007 Proceedings of the American Statistical Association, Salt Lake City, Utah.  [CD-ROM]. 
  94. Foster SB, McIntosh K, Thompson B, Lu M, Yin W, Rich KC, Mendez H, Serchuck LK, Diaz C, Paul ME, Shearer WT.  Increased incidence of asthma in HIV-infected children treatment with highly active antiretroviral therapy in the National Institutes of Health Women and Infants Transmission Study.  J Allergy Clin Immunol 2008; 122:159-65.
  95. Pahwa S, Read J, Yin W, Matthews Y, Shearer WT, Diaz C, Rich K, Mendez H, Thompson B.  CD4/CD8 ratio for diagnosis of HIV-1 infection in infants:  the Women and Infants Transmission Study.  Pediatrics 2008; 122:331-39.
  96. Rossman MD, Thompson B, Frederick M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Rose C, Magira E, Monos D and the ACCESS Group.  HLA and Environmental interactions in Sarcoidosis.  Sarcoidosis Vasculitis and Diffuse Lung Diseases 2008; 25;125-32.
  97. Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, Thompson B, McIntosh K, Meyer WA III, Ha BF, Ross LL, Rich KC, Moye J Jr.  Antiretroviral exposure and lymphocyte mitochondrial DNA content among uninfected infants born to women infected by Human Immunodeficiency Viru-1.  Pediatrics, Dec. 2009; 124;e1189-e1197. 
  98. Thompson BW.  Immune responses in adult female volunteers during bed-rest model of space flight:  Antibodies and cytokines.  J Allergy Clin Immunol 2009.
  99. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, Kazerooni EA, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Freeman C, Landreneau RJ, Wise R, Martinez FJ.  Clinical significance of radiologic characterizations in COPD.  COPD:  Journal of Chronic Obstructive Pulmonary Disease 2009; 6:459-467.
  100. Katz I, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts H, Hughes M, Tuomala R.  Risk Factors for Detectable HIV-1 RNA at Delivery among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study.  J Acquir Immune Defic Syndr. 2010 May;54(1):27-34
  101. Foster S, Lu M, Thompson B, Rich K, Matukas L, Mason R, Winchester R, MacDonald K, Shearer W.  Association between HLA Inheritance and Asthma Medication Use in HIV+ Children.  AIDS 24(13):2133-2135, August 24, 2010.
  102. Thompson BW, Rogers ZR, Miller ST, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC.  The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG): Challenges of Study Design.  Pediatr Blood Cancer 2010;54:250-255.
  103. McCarville MB, Luo Z, Huang X, Rees RC, Rogers ZR, Kalpatthi R, Miller ST, Thompson B, Wang WC.  Abdominal ultrasound findings in infants with sickle cell anemia:  Baseline Data from the BABY HUG Trial.  In Press.
  104. Rogers ZR, Wang WC, Luo Z, Iyer RV, Shalaby-Rana E, Dertinger S, Files B, Lane P, Thompson B, Miller ST, Ware RE,  Shulkin BL, Miller JH.  Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial.  Blood First Edition Paper, prepublished online January 7, 2011.

OTHER WORKS:

  1. Gittelsohn A, Abbey HA, Thompson B.  Cause of death validation NCHS HRA 230-277, final progress report to the National Center for Health Statistics.
  2. Klastersky et al.  Randomized comparison of three antibiotic regimens for empiric therapy of suspected bacteremia infection in febrile granulocytopenic patient.  Antimicrobial Agents and Chemotherapy 29(2): 262-70.

Zhao, Enxu

  1. Performance of Sequential Imputation Method in Multilevel Settings. 2009 Joint Statistical Meetings, Sampling and Survey Methodology Section. Washington, DC: American Statistical Association.
  2. Using SAS to Handle HL7 Messages in a Health Information Exchange. 2009 Northeastern SAS User Group Meeting (NESUG) proceedings. Applications Big & Small Section. Burlington, VT.
  3. Data Quality Control of the BRFSS Asthma Call-Back Survey (ACS) Data. 2008 25th Annual Behavioral Risk Factor Surveillance System Conference. Orlando, FL: Centers for Disease Control and Prevention.
  4. New York State Asthma Surveillance Summary Report, Oct. 2007. http://www.health.state.ny.us/statistics/ny_asthma/pdf/2007_asthma_surveillance_summary_report.pdf
  5. A New Parameter Self-learning Fuzzy Controller Based on Nerve Unit and its programming realization, Journal of Tianjin University, 5, 2003.
  6. The Compensation Method of Dead-band Effect of the Converter in PMSM AC Servo System, Electric Power Electronics Technique, 8, 2003.
  7. Research on the Commutation Algorithm and Error Compensation of BLDCM Servo System, Journal of Tianjin University, 5, 2002.
COMPANY
History
Clients & Partners
Management
Publications

Recent News

C-TASC Exhibits at DIA Conference.

San Diego, CA - November 14, 2011 - Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, exhibited at the 10th DIA ...

C-TASC Published in American Heart Association Journal.

Baltimore, MD - October 24, 2011 - Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, recently co-authored (Sandra ...

C-TASC Hires Ph.D. Senior Statistician.

Baltimore, MD - June 6, 2011 - Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today it has hired Margaret A. Connolly, Ph.D. ...